EULAR European Congress of Rheumatology

Alexis Ogdie, MD: Importance of Patient Experience in Psoriatic Arthritis Treatment

June 14, 2021

In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.

Risankizumab Significantly More Effective Than Placebo in Treating Psoriatic Arthritis

June 10, 2021

Risankizumab showed significantly greater improvements in symptoms of psoriatic arthritis when compared with a placebo and was well tolerated in patients who were intolerant to biologics and conventional synthetic disease-modifying antirheumatic drugs.

Eugen Feist, MD: Olokizumab Emerges as Promising Therapy for Rheumatoid Arthritis

June 10, 2021

Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.

Alyssa Johnsen, MD, PhD: Guselkumab Improves Joint Symptoms and Skin Clearance in Psoriatic Arthritis

June 08, 2021

Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.

Benjamin Nowell, PhD: Mindfulness Program for Patients With Rheumatic Disease

June 08, 2021

Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss the Healthy Mind Healthy You study, which assessed 2 mindfulness programs of varying lengths, designed for people with rheumatic disease, and compared the results.

Roy Fleischmann, MD: Efficacy of Upadacitinib and Adalimumab for Rheumatoid Arthritis

June 04, 2021

Roy Fleischmann, MD, discusses his presentations for EULAR 2021, which include topics about the side effects of JAK inhibitors, disease activity measures of methotrexate withdrawal among patients with rheumatoid arthritis, and the long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis.